Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26483327 · 1 trial · 7 indications
| Name | Type | Description |
|---|---|---|
| JNJ-26483327 | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of solid malignancy that is advanced or refractory and progressing and for which standard treatments do not exist or are no longer effective * radiological assessment of disease within 4 weeks of first study drug administration * overall health status as de...
JNJ-26483327 is an investigational small molecule kinase inhibitor being developed by Johnson & Johnson for the treatment of cancer. It was studied in patients with advanced and/or refractory solid malignancies. It is a Phase 1 research compound and is not an approved medicine.
JNJ-26483327 was studied for the treatment of advanced and/or refractory solid malignancies in adults. The single Phase 1 trial enrolled patients with advanced cancers, including solid tumors, to assess safety and dose finding. It is an investigational agent and is not approved for any use.
JNJ-26483327 is a kinase inhibitor that targets ERBB4, LYN, YES1, EGFR, ERBB2, and FYN. By inhibiting these protein kinases, it is designed to interfere with signaling pathways involved in tumor cell growth and survival. It is a small molecule developed for oncology indications.
JNJ-26483327 is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The compound is an investigational oncology asset from the company's pipeline and has been studied in a single Phase 1 clinical trial.
JNJ-26483327 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The study was an open-label, uncontrolled, non-randomized dose-finding and safety study, so the program remains at the earliest stage of clinical testing.
JNJ-26483327 was evaluated in the Phase 1 trial NCT00676299, titled a safety and dose-finding study for patients with advanced and/or refractory solid malignancies. The trial was completed and enrolled 19 participants aged 18 years and older. No other clinical trials of JNJ-26483327 are listed.